Trovagene Inc. (NASDAQ:TROV) shares dropped 4.5% during trading on Monday . The stock traded as low as $4.75 and last traded at $4.88, with a volume of 273,013 shares. The stock had previously closed at $5.11.

TROV has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Trovagene in a report on Monday, March 28th. Avondale Partners reaffirmed a “market perform” rating and issued a $6.00 price objective on shares of Trovagene in a report on Tuesday, March 29th. Leerink Swann downgraded shares of Trovagene from an “outperform” rating to a “sector perform” rating in a report on Tuesday, April 26th. Maxim Group reaffirmed a “buy” rating on shares of Trovagene in a report on Monday, June 6th. Finally, Piper Jaffray Cos. reaffirmed a “hold” rating and issued a $5.00 price objective (down from $8.00) on shares of Trovagene in a report on Thursday, May 12th. Six investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $6.96.

The stock’s market capitalization is $145.12 million. The company’s 50-day moving average is $4.82 and its 200 day moving average is $4.79.

Trovagene (NASDAQ:TROV) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.07. On average, analysts anticipate that Trovagene Inc. will post ($1.30) earnings per share for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.